Key facts
- This page summarizes Robert E. Abernathy's Form 4 filing for HAEMONETICS CORP (HAE).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 25 Jul 2025, 16:18.
Robert E. Abernathy - 24 Jul 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Role
- Director
- Signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Abernathy
- Issuer symbol
- HAE
- Transactions as of
- 24 Jul 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 25 Jul 2025, 16:18:02 UTC
- Previous filing
- 02 Jul 2025
- Next filing
- 02 Oct 2025
- SEC
- View on sec.gov
Key filing fact
Robert E. Abernathy filed Form 4 for HAEMONETICS CORP (HAE) on 25 Jul 2025.
Change
- Previous filing in this sequence was filed on 02 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001222888
Primary reporting owner
ABERNATHY ROBERT E
- Relationship
- Director
- Address
- 125 SUMMER STREET, BOSTON
- Signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Abernathy
- Signature date
- 25 Jul 2025
Transactions Table
HAE
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,693
- Change %
- +12%
- Price
- Shares after
- 24,981
- Date
- 24 Jul 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. |
| F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |